Extracranial dose and the risk of radiation-induced malignancy after intracranial stereotactic radiosurgery: is it time to establish a therapeutic reference level?
Cyberknife
Extracranial dose
Gamma Knife
Linac
Radiation-induced malignancy
Radiosurgery
SRS
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
25
09
2020
accepted:
01
12
2020
pubmed:
17
12
2020
medline:
5
6
2021
entrez:
16
12
2020
Statut:
ppublish
Résumé
To measure extracranial doses from Gamma Knife Perfexion (GKP) intracranial stereotactic radiosurgery (SRS) and model the risk of malignancy after SRS for different treatment platforms. Doses were measured for 20 patients undergoing SRS on a GKP at distances of 18, 43 and 75 cm from the target, corresponding to the approximate positions of the thyroid, breast and gonads respectively. A literature review was conducted to collect comparative data from other radiosurgery platforms. All data was used to calculate the dose to body organs. The National Cancer Institute (NCI) RadRAT calculator was used to estimate excess lifetime cancer risk from this exposure. Five different age groups covering childhood and younger adults were modelled for both sexes. Extracranial doses delivered during SRS with the GKP were a median 0.04%, 0.008% and 0.002% of prescription dose at 18 cm, 43 cm and 70 cm from the isocentre respectively. Comparison with the literature revealed that the extracranial dose was lowest from GKP, then linacs equipped with micro-multileaf collimators (mMLC), then linacs equipped with circular collimators (cones), and highest from Cyberknife (CK). Estimated lifetime risks of radiation-induced malignancy in the body for patients treated with SRS aged 5-45 years were 0.03-0.88%, 0.36-11%, 0.61-18% and 2.2-39% for GKP, mMLC, cones and CK respectively. We have compared typical extracranial doses from different platforms and quantified the lifetime risk of radiation-induced malignancy. The risk varies with platform. This should be taken into account when treating children and young adults with SRS. The concept of a therapeutic reference level (TRL), similar to the diagnostic reference level (DRL) established in radiology, is proposed.
Sections du résumé
BACKGROUND
To measure extracranial doses from Gamma Knife Perfexion (GKP) intracranial stereotactic radiosurgery (SRS) and model the risk of malignancy after SRS for different treatment platforms.
METHODS
Doses were measured for 20 patients undergoing SRS on a GKP at distances of 18, 43 and 75 cm from the target, corresponding to the approximate positions of the thyroid, breast and gonads respectively. A literature review was conducted to collect comparative data from other radiosurgery platforms. All data was used to calculate the dose to body organs. The National Cancer Institute (NCI) RadRAT calculator was used to estimate excess lifetime cancer risk from this exposure. Five different age groups covering childhood and younger adults were modelled for both sexes.
RESULTS
Extracranial doses delivered during SRS with the GKP were a median 0.04%, 0.008% and 0.002% of prescription dose at 18 cm, 43 cm and 70 cm from the isocentre respectively. Comparison with the literature revealed that the extracranial dose was lowest from GKP, then linacs equipped with micro-multileaf collimators (mMLC), then linacs equipped with circular collimators (cones), and highest from Cyberknife (CK). Estimated lifetime risks of radiation-induced malignancy in the body for patients treated with SRS aged 5-45 years were 0.03-0.88%, 0.36-11%, 0.61-18% and 2.2-39% for GKP, mMLC, cones and CK respectively.
CONCLUSIONS
We have compared typical extracranial doses from different platforms and quantified the lifetime risk of radiation-induced malignancy. The risk varies with platform. This should be taken into account when treating children and young adults with SRS. The concept of a therapeutic reference level (TRL), similar to the diagnostic reference level (DRL) established in radiology, is proposed.
Identifiants
pubmed: 33325003
doi: 10.1007/s00701-020-04664-4
pii: 10.1007/s00701-020-04664-4
pmc: PMC7966618
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
971-979Commentaires et corrections
Type : CommentIn
Références
BEIR VII Phase 2. Health risks from exposure to low levels of ionizing radiation. Washington, D.C.: The National Academies Press; 2006. Available from: http://www.nap.edu/catalog/11340 Accessed 03 Mar 2019
Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD et al (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12(4):353–360
doi: 10.1016/S1470-2045(11)70061-4
Boice JD Jr (2012) Radiation epidemiology: a perspective on Fukushima. J Radiol Prot 32(1):N33–N40
doi: 10.1088/0952-4746/32/1/N33
Cashmore J, Ramtohul M, Ford D (2011) Lowering whole-body radiation doses in pediatric intensity-modulated radiotherapy through the use of unflattened photon beams. Int J Radiat Oncol Biol Phys 80(4):1220–1227
doi: 10.1016/j.ijrobp.2010.10.002
Council NR (2006) Health risks from exposure to low levels of ionizing radiation. Washington, D.C.: National Academies Press; 2006 http://www.nap.edu/catalog/11340 Accessed 14 Feb 2018
Cousins C, Boice Jr J, Cooper UJ, Lee UJ, Lochard KJ (2018) Annals of the ICRP published on behalf of the International Commission on Radiological Protection International Commission on Radiological Protection Members of the 2010–2013 Main Commission of ICRP. Available from: http://journals.sagepub.com/doi/pdf/10.1177/ANIB_37_2-4 Accessed 08 May 2018
de Gonzalez AB, Iulian Apostoaei A, Veiga LHS, Rajaraman P, Thomas BA, Owen Hoffman F et al (2012) RadRAT: a radiation risk assessment tool for lifetime cancer risk projection. J Radiol Prot 32(3):205–222
doi: 10.1088/0952-4746/32/3/205
Department of Health (2000) The Ionising Radiation (Medical Exposure) Regulations. London: The Stationery Office. http://www.legislation.gov.uk/uksi/2000/1059/pdfs/uksi_20001059_en.pdf Accessed 21 Mar 2017
Di Betta E, Fariselli L, Bergantin A, Locatelli F, Del Vecchio A, Broggi S et al (2010) Evaluation of the peripheral dose in stereotactic radiotherapy and radiosurgery treatments. Med Phys 37(7):3587–3594
doi: 10.1118/1.3447724
Diallo I, Haddy N, Adjadj E, Samand A, Quiniou E, Chavaudra J et al (2009) Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 2009 74(3):876–883
doi: 10.1016/j.ijrobp.2009.01.040
Elmore E, Lao X-Y, Kapadia R, Redpath JL (2006) The effect of dose rate on radiation-induced neoplastic transformation in vitro by low doses of low-LET radiation. Radiat Res 166(6):832–838
doi: 10.1667/RR0682.1
Feinendegen LE (2005) Evidence for beneficial low level radiation effects and radiation hormesis. Br J Radiol 78(925):3–7
doi: 10.1259/bjr/63353075
Gevaert T, Desmedt F, Vanderlinden B, Schaeken B, Van Ranst C, Storme G et al (2006) In vivo estimation of extracranial doses in stereotactic radiosurgery with the Gamma Knife and Novalis Systems. In: Radiosurgery. Basel, KARGER, pp 36–49
doi: 10.1159/000093714
Harrison R (2017) Out-of-field doses in radiotherapy: Input to epidemiological studies and dose-risk models. Phys Med 42:239–246
doi: 10.1016/j.ejmp.2017.02.001
Health D of. On the State of the Public Health (1995) In introduction to the annual report of the Chief Medical Officer of the Department of Health for the year 1995, London
Huang JY, Followill DS, Wang XA, Kry SF (2013) Accuracy and sources of error of out-of field dose calculations by a commercial treatment planning system for intensity-modulated radiation therapy treatments. J Appl Clin Med Phys 14(2):4139
doi: 10.1120/jacmp.v14i2.4139
Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA et al (2005) The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62(4):1195–1203
doi: 10.1016/j.ijrobp.2005.03.053
Lindquist C, Paddick I (2007) The Leksell Gamma Knife Perfexion and comparisons with its predecessors. Neurosurgery. 61(September):130–141
pubmed: 17876243
Maarouf M, Treuer H, Kocher M, Voges J, Gierich A, Sturm V (2005) Radiation exposure of extracranial organs at risk during stereotactic linac radiosurgery. Strahlentherapie und Onkol 181(7):463–467
doi: 10.1007/s00066-005-1391-x
Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB et al (2013) Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 346:f2360
doi: 10.1136/bmj.f2360
NHS England (2015) Clinical commissioning policy: proton beam radiotherapy (high energy) for paediatric cancer treatment - NHS Overseas Programme (B01/P/b Proton Beam Therapy for Cancer in Children). https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/b01-pb-pd-prtn-bm-thrpy-chld-oct15.pdf Accessed 02 May 2017
NHS England (2016) Service specifications: stereotactic radiosurgery and stereotactic radiotherapy (Intracranial) (All ages). London. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/09/mstr-specification-srs-srt-11-4-16.pdf Accessed 15 Feb 2018
Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP et al (2012) Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 380(9840):499–505
doi: 10.1016/S0140-6736(12)60815-0
Petti PL, Chuang CF, Smith V, Larson DA (2006) Peripheral doses in CyberKnife radiosurgery. Med Phys 33(6):1770–1779
doi: 10.1118/1.2198173
Richardson DB, Cardis E, Daniels RD, Gillies M, Jacqueline A, Hagan O et al (2015) Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States. BMJ 351:h5359
doi: 10.1136/bmj.h5359
Rowe J, Grainger A, Walton L, Silcocks P, Radatz M, Kemeny A (2007) Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 60(1):60–65
doi: 10.1227/01.NEU.0000255492.34063.32
Sharma S (2011) Unflattened photon beams from the standard flattening filter free accelerators for radiotherapy: advantages, limitations and challenges. J Med Phys 36(3):123
doi: 10.4103/0971-6203.83464
Tien CJ, Lee S (2014) Estimated clinical impact of fractionation scheme and tracking method upon imaging dose in Cyberknife Robotic Radiosurgery. Austin J Nucl Med Radiother 1(1):1–5
Vlachopoulou V, Antypas C, Delis H, Tzouras A, Salvaras N, Kardamakis D et al (2011) Peripheral doses in patients undergoing Cyberknife treatment for intracranial lesions. A single centre experience. Radiat Oncol 6(1):157
doi: 10.1186/1748-717X-6-157
Xu XG, Bednarz B, Paganetti H (2008) A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 53(13):R193–R241
doi: 10.1088/0031-9155/53/13/R01